[Skip to Content]
[Skip to Content Landing]
Views 510
Citations 0
Editor's Correspondence
May 13, 2013

New Oral Anticoagulants in Acute Coronary Syndromes: What Does a Meta-analysis Tell Us?

Author Affiliations

Author Affiliations: Institute of Vascular Medicine, Li Ka Shing Institute of Health Sciences, S. H. Ho Cardiovascular Disease and Stroke Centre, Heart Education And Research Training (HEART) Centre and Division of Cardiology, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Special Administrative Region (SAR).

JAMA Intern Med. 2013;173(9):835-836. doi:10.1001/jamainternmed.2013.78

We read with interest the meta-analysis by Komócsi et al, which reported that the use of factor Xa and direct thrombin inhibitors in patients receiving antiplatelet therapy after an acute coronary syndrome (ACS) was associated with a substantial increase in major bleeding and moderate reduction in ischemic events.1 However, there are a few issues we would like to highlight.

First Page Preview View Large
First page PDF preview
First page PDF preview
×